The Effect of Vaginal Sildenafil on The Outcome of Assisted Reproductive Technology Cycles in Patients with Repeated Implantation Failures: A Randomized Placebo-Controlled Trial

Ashraf Moini, M.D.1,2,3, Fatemeh Zafarani, M.Sc.4, Nadia Jahangiri, M.Sc.1, Shahideh Jahanian Sadatmahalleh, Ph.D.5, Marya Sadeghi, M.Sc.1, Mohammad Chehrazi, Ph.D.6, Firoozeh Ahmadi, M.D.4*

1. Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
2. Department of Obstetrics and Gynaecology, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Obstetrics and Gynaecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
5. Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
6. Department of Biostatistics and Epidemiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran

Abstract

Background: The aim of this study was to investigate the effects of vaginal sildenafil on the outcome of patients with at least two unsuccessful in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) attempts.

Materials and Methods: In this randomized placebo-controlled trial study, a total of 66 infertile women aged ≤38 years, with a history of normal ovarian reserve, two prior consecutive failed IVF/ICSI attempts, human chorionic gonadotropin (hCG) day endometrial thickness <7 mm in all prior IVF/ICSI cycles, normal endometrial appearance by either hysteroscopy, hysterosonography, or hysterosalpingography enrolled in this study. The conventional gonadotropin-releasing hormone (GnRH) protocol was used for ovarian stimulation. The patients were randomly divided into three groups: vaginal sildenafil (suppository-100 mg/daily), vaginal placebo/sildenafil (suppository-100 mg/daily), and vaginal placebo (suppository). Each patient underwent colour Doppler ultrasound on day 14 of their previous cycle to investigate any abnormalities in the uterus and adnexa. Endometrial thickness, echo pattern, uterine artery resistance, and pulsatility indices were recorded pre- and post-treatment. The primary outcome measures were implantation, chemical and clinical pregnancy rates. For data analysis, SPSS version 20 software was used. In all tests, the significance level was considered less than 0.05.

Results: There was no significant difference between three groups in endometrial thickness on the hCG injection day. The chemical pregnancy in women who received sildenafil (alone or in combination with placebo) showed a two-fold increase in comparison to the placebo group. This increase was clinically meaningful, but according to sample size, it was statistically non-significant. The results of our study showed that the implantation was higher in women who received placebo/sildenafil compared to the other groups. The abortion rate was not statistically significant among the groups.

Conclusion: Vaginal sildenafil may conceivably improve chemical pregnancy rates in repeated IVF failure patients. Further randomized clinical trials using oral or vaginal sildenafil with higher sample size are recommended (Registration number: NCT03192709).

Keywords: Outcome, Repeated Implantation Failure, Sildenafil Citrate, Thin Endometrium

Introduction

Successful implantation of an embryo requires a receptive endometrium, a good quality embryo, and embryo-endometrial synchronization in all species (1).

Endometrial receptivity during the implantation window is often assessed by ultrasonography markers such as endometrial thickness, echogenic pattern, blood flow, and biochemical markers (2). An appropriately thickened endometrium is a crucial factor for embryo implantation and can predict pregnancy outcome with high sensitivity and specificity (3). Moreover, several studies have reported a
significant positive correlation between a triple-layered thickened endometrium of 7 mm (preferably >9 mm) and pregnancy rate (3-5).

Despite significant advances in ovarian stimulation protocols, treatment of repeated, unresponsive thin endometrium is still a challenge in assisted reproductive cycles, which usually results in cycle cancellation or repeated implantation failures (6).

There is a growing body of evidence that the endometrial growth has a relationship with the state of uterine blood flow (2). Treatment options, such as low-dose aspirin, oestradiol administration and gonadotropin therapy, low dose human chorionic gonadotropin (hCG), vitamin E, pentoxifylline, L-arginine, luteal phase support with gonadotropin-releasing hormone (GnRH) agonist, intravaginal granulocyte colony-stimulating factor (G-CSF), vaginal sildenafil, and recent application of stem cell therapy are suggested for management of a thin lining endometrium (7).

Sildenafil citrate (Viagra®, Pfizer, NY, USA) is a 5-phosphodiesterase inhibitor that increases smooth muscle relaxation and vasodilation by preventing cGMP breakdown (8). Sildenafil citrate potentiates uterine blood flow and, in conjunction with oestrogen, it leads to the oestrogen-induced proliferation of the endometrium (9).

It has been reported that vaginal sildenafil significantly reduced peripheral natural killer cell (NK-cell) activity and improved successful pregnancy rates in women with histories of recurrent miscarriages. Although the mechanism of influence by sildenafil on natural killer cell activity is unclear, it seems that enhancement of uterine artery flow has an effective influence on the local endometrial NK-cell population (10). However, adverse effects that include myocardial infarctions and strokes have been associated with this drug in the normal healthy population (11, 12).

This comparative pilot study evaluated the effect of vaginal sildenafil suppositories on endometrial proliferation and IVF outcome in infertile patients with a history of repeated IVF failure.

Materials and Methods

Patients

This phase II randomized, double-blind, placebo-controlled trial was performed at Royan Institute, Reproductive Biomedicine Research Center, Tehran, Iran, between February 14, 2014 and November 14, 2016 (NCT03192709). The assessors and patients were not aware of the treatment allocated. The Institutional Review Board and Ethics Committee of Royan Institute, Tehran, Iran reviewed and approved this study in compliance with the Declaration of Helsinki (EC/88/1045). Informed consent was obtained from all patients prior to their participation in the study.

The study population consisted of 66 infertile women aged ≤38 years. The inclusion criteria was met when the women had normal ovarian reserve [blood anti-mullerian hormone (AMH) levels >1.5 ng/mL] with at least two prior cycles with follicle stimulating hormone (FSH) <10 mIU/ml; a history of two prior consecutive failed IVF/ICSI attempts with at least a transfer of two good quality fresh or frozen-thawed embryos; hCG day endometrial thickness <7 mm in all prior IVF/ICSI attempts; and normal endometrial appearance according to either hysterosonography, hysterosalpingography, or hysteroscopy. Women were excluded if they had a history of myome- tomy or Asherman’s syndrome.

Treatment cycle

A preliminary colour Doppler transvaginal sonography with a 4–8 MHz probe (ProSound Alpha 10; Aloka, Japan) was performed by an expert radiologist on day 14 of the patient’s prior menstrual cycle to investigate the uterine and adnexes for any abnormal findings. The endometrial parameters of endometrial thickness, endometrial pattern, pulsatility index (PI), and resistance index (RI) were measured. The uterine artery PI and RI were obtained through flow velocity waveforms from the ascending branch of the uterine artery at the point near to the internal cervical orifice and calculated as previously described (13). In the subsequent cycle, ovarian stimulation was performed with the long protocol using a GnRH agonist (14).

In the IVF treatment cycle, the patients were randomly assigned to three groups according to a random allocation sequence generated by a randomized block design. The size of each block was 3. In group A, the sildenafil (vaginal suppositories, 100 mg/day, Parnian Daroo, Co., Tehran, Iran) were administered from the first day of the FSH injection until the day of oocyte retrieval. In group B, placebo (vaginal suppositories, Parnian Daroo, Co., Tehran, Iran) was initiated from the first day of the HMG injection until 2 days before the hCG injection, after which sildenafil vaginal suppositories were initiated and continued until the day of oocyte retrieval. In group C, the placebo was given from the first day of HMG injection until the day of oocyte retrieval. Participants received 10 000 IU of hCG (Chorimon, IBSA, Switzerland) when at least two dominant follicles were 18 mm in diameter. Endometrial thickness, pattern, PI and RI were measured on the day of hCG administration and compared with the data obtained in the previous cycle without sildenafil citrate treatment. Oocytes were retrieved 36 hours later via transvaginal ultrasound-guided needle aspiration.

Embryo transfer was performed after 48 hours of oocyte retrieval. Progesterone in oil (100 mg, IM daily) or intravaginal progesterone (400 mg, twice daily) was used for luteal support and maintained until the pregnancy test was conducted. Serum hCG levels were measured on the 14th day following oocyte retrieval. Vaginal ultrasound confirmation of pregnancy was performed at 4-6 weeks after embryo transfer.

A chemical pregnancy was determined by a positive β-hCG test result. A clinical pregnancy was confirmed by ultrasonography visualization of one or more gestational sacs or definitive clinical signs of pregnancy. The spontaneous abortion was defined as a pregnancy...
loss of an intrauterine pregnancy before 22 weeks’ gestation (15).

Suppositories containing 100 mg of sildenafil were prepared from the oral tablets by a local pharmacy (Parnian Daroo, Iran). We defined the endometrial thickness threshold cut-off of <7 mm as a thin endometrium based on other studies (8).

**Statistical analysis**

Data are expressed as mean ± standard error (SE) and proportion. Continuous and categorical outcome variables were compared between three intervention groups by one-way analysis of variance (ANOVA) and the chi-square test. All statistical analyses were performed using SPSS version 22 for Windows 7 (IBM Analytics, Armonk, NY). The significance level was set at 0.05.

**Results**

During the recruitment process, we enrolled 66 patients and allocated 22 patients to each study group. A total of 10 patients were lost to follow up for measuring clinical pregnancy for the following reasons: all of the embryos of their treatment cycle were cryopreserved (n=3), they had no oocytes at retrieval (n=2), or no embryos to transfer (n=5). The flow diagram explicitly shows the number of participants at the beginning, intervention allocation, follow-up, and analysis (Fig.1).

Table 1 shows the baseline characteristics of the three study groups. There were no significant differences among the study groups. The majority of patients had normal endometrial patterns, which were similar between the three study groups (Table 1). Uterine artery PI and RI in the left and right were not statistically significant among the study groups (P>0.05). Table 1 shows the results of the ovulation stimulation cycle and include initial endometrial thickness, number and type of ampoules used, time interval for ovulation stimulation, and numbers of total and metaphase II (MII) oocytes. These parameters did not differ significantly among the three intervention groups. Table 2 shows numbers of embryos transferred in total and by grade (A, B and C). These values were not different among the groups. The generated embryos were graded as good (A and B) or poor (C) according to their morphological features, cleavage stage, multi-nucleation, equal size blastomeres, and fragmentation rate (16).

Of note, the embryo transfer days were similar between the three groups. All of the embryos were transferred either two or three days after ovum pickup.

**Comparisons after the interventions**

The endometrial thickness and patterns after the interventions were not statistically different between the study groups. Additionally, the three intervention groups were not different in left and right uterine artery PI and RI. Implantation rate was not statistically significant over the three groups (P=0.290). Clinical pregnancy rates were 33.3 (sildenafil), 33.3 (sildenafil+placebo), and 17.6 (placebo) as seen in Table 2. Although the clinical pregnancy rates varied among the intervention groups, they were not statistically different (Table 3). Vaginal administration of sildenafil had no adverse effects on the patients during the study.

![Fig.1: Flowchart of participants in this randomized controlled trials. IVF/ICSI; In vitro fertilization/intracytoplasmic sperm injection and ET; Embryo transfer.](image-url)
Table 1: Comparison of baseline characteristics and cycle related factors between the sildenafil, sildenafil + placebo, and placebo groups prior to intervention

| Variable                      | Sildenafil  | Sildenafil + placebo | Placebo  | P value |
|-------------------------------|-------------|----------------------|----------|---------|
|                               | n=22        | n=22                 | n=22     |         |
| Age (Y)                       | 33.2 ± 4.6  | 31.7 ± 4.8           | 32.8 ± 4.6 | 0.568   |
| BMI (kg/m²)                   | 24.7 ± 3.7  | 26.2 ± 3.6           | 25.2 ± 2.9 | 0.379   |
| Infertility duration          | 8.8 ± 4.9   | 10.5 ± 5.1           | 8 ± 4.1  | 0.220   |
| Infertility type              |             |                      |          |         |
| Primary                       | 19 (86.4)   | 20 (90.9)            | 17 (77.3) |         |
| Secondary                     | 3 (13.6)    | 2 (9.1)              | 5 (22.7) | 0.438   |
| Infertility reason            |             |                      |          |         |
| Tubal factor                  | 1 (4.5)     | 1 (4.5)              | 1 (4.5)  | 0.910   |
| Male factor                   | 14 (63.6)   | 11 (50)              | 11 (50)  |         |
| Endometrosis                  | 0 (0)       | 0 (0)                | 1 (4.5)  |         |
| Unexplained                   | 1 (4.5)     | 2 (9.1)              | 1 (4.5)  |         |
| Two or more                   | 6 (27.3)    | 8 (36.4)             | 8 (36.4) |         |
| Endometrial pattern           |             |                      |          |         |
| Normal                        | 18 (81.8)   | 18 (81.8)            | 19 (86.4) |         |
| Heterogenic                   | 2 (9.1)     | 3 (13.6)             | 3 (13.6) | 0.683   |
| Ecogene                       | 2 (9.1)     | 1 (4.5)              | 0        |         |
| Uterine artery PI             |             |                      |          |         |
| Right                         | 2.4 ± 0.7   | 2.5 ± 0.7            | 2.9 ± 0.9 | 0.134   |
| Left                          | 2.5 ± 0.8   | 2.7 ± 0.9            | 2.9 ± 1  | 0.440   |
| Uterine artery RI             |             |                      |          |         |
| Right                         | 80.1 ± 19.3 | 69.7 ± 32.7          | 74.2 ± 31.2 | 0.474 |
| Left                          | 76.5 ± 25.2 | 66.4 ± 35.7          | 74 ± 31  | 0.527   |
| Endometrial thickness         | 8.0 ± 2.4   | 8.9 ± 2.0            | 7.6 ± 2.1 | 0.146   |
| Type of gonadotropins         |             |                      |          |         |
| FSH (75 IU/mL)                | 5 (22.7)    | 8 (36.4)             | 3 (13.6) | 0.209   |
| FSH+LH (75 IU/mL)             | 17 (77.3)   | 14 (63.6)            | 19 (86.4) |         |
| Ovulation duration            | 9.9 ± 2.1   | 10.3 ± 2.2           | 9.1 ± 1.3 | 0.100   |
| Ampoules (n)                  | 9.1 ± 12.2  | 9.6 ± 14.6           | 7.8 ± 8.5 | 0.871   |
| Oocytes (n)                   | 11.5 ± 5.6  | 11.6 ± 6.7           | 8.1 ± 5.5 | 0.098   |
| MII (n)                       | 9.3 ± 5.1   | 9.4 ± 5.8            | 6.3 ± 4.1 | 0.079   |

BMI: Body mass index; PI: Pulsatility index, FSH: Follicle stimulating hormone, LH: Luteinizing hormone, RI: Resistance index, and MII: Mature metaphase II.

Table 2: Comparison of treatment cycle outcomes between the sildenafil, sildenafil + placebo, and placebo groups after intervention

| Variable                      | Sildenafil  | Sildenafil + placebo | Placebo  | P value |
|-------------------------------|-------------|----------------------|----------|---------|
|                               | n=22        | n=22                 | n=22     |         |
| Endometrial pattern           |             |                      |          |         |
| Normal                        | 17 (77.3)   | 21 (95.5)            | 20 (90.9) | 0.263   |
| Heterogenic                   | 3 (13.6)    | 0                    | 2 (9.1)  |         |
| Ecogene                       | 2 (9.1)     | 1 (4.5)              | 0        |         |
| Uterine artery PI             |             |                      |          |         |
| Right                         | 2.1 ± 0.6   | 2.2 ± 0.7            | 2.0 ± 0.5 | 0.515   |
| Left                          | 2.2 ± 0.4   | 2.3 ± 0.7            | 2.1 ± 0.3 | 0.357   |
| Uterine artery RI             |             |                      |          |         |
| Right                         | 79.8 ± 7.0  | 82.3 ± 5.9           | 80.0 ± 5.0 | 0.318   |
| Left                          | 78.2 ± 18.1 | 79.0 ± 18.2          | 81.5 ± 4.0 | 0.747   |
| Endometrial thickness         | 10.1 ± 2.4  | 10.30 ± 2.5          | 9.60 ± 2.5 | 0.656   |
| Embryo (n)                    | 4.8 ± 3.3   | 4.80 ± 2.7           | 3.60 ± 3.2 | 0.322   |
| ET (n)                        | 2.5 ± 1.2   | 2.20 ± 1.4           | 2.10 ± 1.6 | 0.603   |
| ET grade                      |             |                      |          |         |
| A                             | 2.1 ± 2.0   | 2.13 ± 2.3           | 2.14 ± 2.2 | >0.999 |
| B                             | 1.0 ± 1.0   | 1.0 ± 1.1            | 1.0 ± 1.1 | 0.957   |
| C                             | 0.4 ± 0.8   | 0.10 ± 0.3           | 0.40 ± 1.0 | 0.555   |

PI: Pulsatility index, RI: Resistance index, and ET: Embryo transfer.
Discussion

The importance of the endometrial pattern as a predictor of treatment cycle outcome in IVF-treated patients is well-documented (17). In addition, endometrial quality is also an important factor for the successful implantation of the foetus (18). Endometrial thickness increases with high pregnancy rates; however, pregnancy rates are not predictable only based on endometrial thickness (19). Uterine arterial blood flow seems to affect endometrial growth and the outcome of pregnancy. Studies have shown that sildenafil widens the vasculature by its effects on the smooth muscles of the arteries (10, 20). Sildenafil citrate is an inhibitor-5-phosphodiesterase type that, by preventing the effect of cGMP, exacerbates the effect of NO on the smooth muscle of the arteries (20, 21). According to the results of some studies, the use of sildenafil during the proliferative phase of the cycle improves uterine blood flow and endometrial growth, and results in a higher level of implantation and pregnancy in patients with repeated IVF failure and Asherman syndrome (8, 22). Also the administration of sildenafil (50 mg intravenous) in a sterilized animal model (sheep) has been shown to exacerbate uterine flow (23). Several studies have shown a correlation between “thin endometrium” and low implantation rates (9, 24). The results of current study showed increased endometrial thickness in the three groups on the day of hCG injection, but the increase was not statistically significant. The results of previous studies have shown that sildenafil citrate (vaginal or oral alone or with oestradiol) is significantly effective in improving endometrial thickness (25-27). Sher and Fisch (22) reported that the use of sildenafil vaginal suppository could reduce the adverse effects of headache and low blood pressure compared with oral sildenafil. In another study, they reported that vaginal sildenafil (25 mg, 4 times per day) improved endometrial thickness (≥9 mm) in 70% of the patients (8). In a prospective study, Takasaki et al. (25) compared the effects of vaginal vitamin E, L-arginine, and vaginal sildenafil citrate on endometrial thickness in patients with endometrial thickness less than 8 mm and right arterial resistance in their radial vessels (RA-RI ≥0.81). The results showed that vitamin E, L-arginine, and sildenafil citrate significantly improved RA-RI and endometrial thickness in these patients; however, the improvement in endometrial thickness in patients treated with sildenafil citrate was more than the other two groups. Several studies (26-28) showed that vaginal sildenafil significantly improved endometrial thickness in patients with history of poor endometrial thickness in the previous cycles. Jerzak et al. (10) reported that endometrial thickness significantly increased after administration of oral sildenafil (25 mg, 4 times per day) in women with a history of abortion. Dehghani Firouzabadi et al. (29) recommended oral sildenafil administration as an appropriate solution for improving endometrial admission in patients with unsuccessful cycles from low endometrial thickness. Their results showed that the triple line endometrial pattern in the sildenafil citrate + oestradiol group was significantly higher than in the oestradiol-only group, while the intermediate pattern of the endometrium was not significantly different between the two groups. Fetih et al. (30) reported that sildenafil vaginal gel significantly increased endometrial thickness and uterine blood flow, and might improve pregnancy rate in patients with clomiphene citrate (CC) failure due to thin endometrium. The results reported by Chanona et al. (31) showed that the use of vaginal sildenafil in patients whose endometrial thickness was equal to or less than 7 mm in the failed assisted reproductive technology (ART) cycles led to an increase in implantation and pregnancy. Zinger et al. (32) reported that two patients with a history of curettage and secondary infertility were treated with sildenafil after removing adhesions by surgery (due to thin endometrial thickness in previous IVF cycles), and both patients became pregnant during the first cycle of sildenafil administration. Increases in their endometrial thicknesses was also shown in transvaginal ultrasonography.

Several treatment modalities have been offered to patients with “thin” endometrium, including hormonal manipulation by oestrogen and gonadotropin therapy, low-dose hCG, tamoxifen, L-arginine or sildenafil, vitamin E, pentoxifylline, low-dose aspirin, hysteroscopic adhesiolysis, intrauterine infusion of growth factor such as G-CSF, and the recent application of regenerative medicine. Despite the large variety of treatment, most options lead to only minor modifications in the endometrium thickness and subsequent pregnancy, and when this modality fails, patients are eventually candidates for surrogacy. Treatment of thin endometrium remains a challenge and future investigations are required to further clarify and ideally manage patients with thin endometrium (7).

In the present study, the clinical and chemical pregnancy rates in the two groups of women who were taking sildenafil alone and the women who took placebo
and sildenafil showed a twofold increase compared to the placebo-only-treated women, which according to the sample size, this increase is not significant. The results reported by Dehghani Firouzabadi et al. (29) in a study of 80 patients showed that the chemical pregnancy rate was higher but not statistically significant in the patients who used sildenafil; this finding was consistent with the results of our study. However, AbdelKader Fahmy et al. (33), with a sample size of 70 patients, reported a significantly greater chemical pregnancy rate in the sildenafil group.

In this study, the clinical pregnancy rate was higher in the sildenafil and sildenafil+placebo groups than in the placebo group. Although this increase was not statistically significant, it was clinically shown to be twofold. These results were consistent with the findings of AbdelKader Fahmy et al. (33) and Kim et al. (28). The study by AbdelKader Fahmy et al. (33) reported a 2.5-fold increase in pregnancy in the sildenafil group, but this difference was not statistically significant. Kim et al. (28) reported that the use of vaginal sildenafil plus oral oestrogen pills in the luteal phase of patients treated with an IVF-ET cycle increased the pregnancy rate by two-fold, but this increase was not statistically significant. Mangal and Mehrirshi (34) showed that the rate of pregnancy in the patients who used vaginal sildenafil in three successive intra uterine insemination (IUI) cycles was significantly higher in the third cycle than in the group who used oestradiol valerate, while this difference was not significant in the first and second cycles. The findings from a retrospective study by Margreiter et al. (35) showed a significant improvement in the rate of implantation, endometrial thickness and pregnancy, and decreased abortion in the group of patients treated with vaginal sildenafil.

The endometrial receptivity is an important stage in the ART cycles, the results of our study showed a higher rate of implantation in the women who took sildenafil+placebo than in the other two groups, which was consistent with the results of Dehghani Firouzabadi et al. (29).

In the present study, 2 out of 7 cases of pregnancy ended in abortion in the sildenafil group, 1 out of 6 cases of pregnancy in the sildenafil+placebo group, and 0 of 3 cases of pregnancy in the placebo group. The rate of abortion was negligible in the sildenafil group. Follow-up evaluations showed a molar pregnancy in the sildenafil group. Dzieciol et al. (36) reported that sildenafil citrate increased uterine tissue perforation during the uterus preparation for fertility.

In our study, higher numbers of MII oocytes were retrieved in the sildenafil groups compared to the placebo group, which was clinically important; however, one-way ANOVA results showed that this finding was not statistically significant. To our knowledge, there is only one study (abstract available) by Vidal et al. (37) that provided evidence of the benefit of sildenafil supplementation in the first days of hyperstimulation induction in terms of the numbers of mature and fertilized oocytes. Therefore, more research on this topic needs to be undertaken.

Conclusion

Vaginal sildenafil might conceivably improve chemical and clinical pregnancy rates in repeated IVF failure patients. Since this was a pilot study, we recommend that clinical trials should be conducted with vaginal or oral sildenafil on larger numbers of these patients.

Acknowledgements

The authors would like to express their appreciation to the patients who participated in this study. This study was financially supported by Royan Institute. There was no conflict of interest.

Authors’ Contributions

A.M.; Contributed to conception, study design and evaluation. F.Z.; Participated in data collection, extensively in interpretation of the data and the conclusion, and drafting of manuscript. N.J., Sh.J.S.; Participated in data interpretation, conclusion and drafting of manuscript. M.S.; Participated in acquisition of data and data interpretation. M.Ch.; Contributed to study design and data analysis. F.A.; Participated in acquisition of data, interpretation and conclusion. All authors reviewed and approved the final manuscript.

References

1. Singh M, Chaudhry P, Asselin E. Bridging endometrial receptivity and implantation: network of hormones, cytokines, and growth factors. J Endocrinol. 2011; 210(1): 5-14.
2. Wang J, Xia F, Zhou Y, Wei X, Zhuang Y, Huang Y. Association between endometrial/subendometrial vasculature and embryo transfer outcome: a meta-analysis and subgroup analysis. J Ultrasound Med. 2018; 37(1): 149-163.
3. Zhao J, Zhang Q, Li Y. The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles. Reprod Biol Endocrinol. 2012; 10: 100.
4. Holden EC, Dodge LE, Sneeringer R, Moragianvi NA, Penzias AS, Hacker MR. Thicker endometrial linings are associated with better IVF outcomes: a cohort of 6331 women. Hum Fertil (Camb). 2017; 21(4): 288-293.
5. Ahmadi F, Akhbari F, Zamani M, Ramezanali F, Cheraghl R. Value of endometrial thickness and implantation failure (RIF). J Assist Reprod Genet. 2012; 29(11): 1227-1239.
6. Simon A, Laufer N. Assessment and treatment of repeated implantation failure (RIF). J Assist Reprod Genet. 2012; 29(11): 101-104.
7. Lebovitz O, Orvieto R. Treating patients with "thin" endometrium - an ongoing challenge. Gynecol Endocrinol. 2014; 30(6): 409-414.
8. Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril. 2002; 78(5): 1073-1078.
9. Richter KS, Bugge KR, Bromer JG, Levy MJ. Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos. Fertil Steril. 2007; 87(1): 53-59.
10. Jerzak M, Knietek M, Mrozek J, Górska A, Baranowski W. Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage. Fertil Steril. 2008; 90(5):1848-1853.
11. Cakmak HA, Ikitimur B, Karadag B, Ongen Z. An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. BMJ Case Rep. 2012; 2012: bcr201206504.
12. Feenstra J, van Drie-Pierik RJ, Laclé CF, Stricker BH. Acute myocardial infarction associated with sildenafil. Lancet. 1998; 352(9132): 957-958.
13. Dickey RP. Doppler ultrasound investigation of uterine and ovarian
blood flow in infertility and early pregnancy. Hum Reprod Update. 1997; 3(5): 467-503.

14. Madani T, Ashrafi M, Jahangiri N, Abadi AB, Lankarani N. Improvement of pregnancy rate by modification of embryo transfer technique: a randomized clinical trial. Fertil Steril. 2010; 94(6): 2424-2426.

15. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. Fertil Steril. 2017; 108(3): 393-406.

16. Baczkowski T, Kurzawa R, Glabowski W. Methods of embryo scoring in in vitro fertilization. Reprod Biol. 2004; 4(1): 5-22.

17. Sher G, Herbert C, Maassarani G, Jacobs MH. Assessment of the late proliferative phase endometrium by ultrasonography in patients undergoing in-vitro fertilization and embryo transfer (IVF/ET). Hum Reprod. 1991; 6(2): 232-237.

18. Sher G, Dodge S, Maassarani G, Knutzen V, Zouves C, Feinman M. Management of suboptimal sonographic and endometrial patterns in patients undergoing in-vitro fertilization and embryo transfer. Hum Reprod. 1993; 8(3): 347-349.

19. Kovacs P, Matyas S, Boda K, Kaali SG. The effect of endometrial thickness on IVF/ICSI outcome. Hum Reprod. 2003; 18(11): 2337-2341.

20. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998; 159(6): 2164-2171.

21. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996; 78(2): 257-261.

22. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod. 2000; 15(4): 806-809.

23. Zoma WD, Baker RS, Clark KE. Effects of combined use of sildenafil citrate (Viagra) and 17beta-estradiol on ovine coronary and uterine hemodynamics. Am J Obstet Gynecol. 2004; 190(5): 1291-1297.

24. Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JW. Endometrial thickness: a predictor of implantation in ovum recipients? Hum Reprod. 1994; 9(2): 363-365.

25. Takasaki A, Tamura H, Miwa I, Taketani T, Shimamura K, Sugino N. Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium. Fertil Steril. 2010; 93(6): 1851-1858.

26. Al-Assadi AF, Al-Rubaye SA, Laalby Z. The effect of Sildenafil on endometrial characters in patients with infertility. Tikrit Medical Journal. 2012; 18(2): 330-338.

27. Paulus WE, Strehler E, Zhang M, Melnikova L, El-Danasouri I, Sterzik K. Benefit of vaginal sildenafil citrate in assisted reproduction therapy. Fertil Steril. 2002; 77(4): 846-847.

28. Kim KR, Lee HS, Ryu HE, Park CY, Min SH, Park C, et al. Efficacy of luteal supplementation of vaginal sildenafil and oral estrogen on pregnancy rate following IVF-ET in women with a history of thin endometria: a pilot study. J Womens Med. 2010; 3(4): 155-158.

29. Dehghanifiroozabad R, Davar R, Hojjat F, Mahdavi M. Effect of sildenafil citrate on endometrial preparation and outcome of frozen-thawed embryo transfer cycles: a randomized clinical trial. Iran J Reprod Med. 2013; 11(2): 151-158.

30. Felth AN, Habib DM, Abdelaal II, Hussein M, Felth GN, Othman ER. Adding sildenafil vaginal gel to clomiphene citrate in infertile women with prior clomiphene citrate failure due to thin endometrium: a prospective self-controlled clinical trial. Facts Views Vis Obgyn. 2017; 9(1): 21-27.

31. Chanona J, Garcia M, Ruvalcaba L, Bermudez A, Muniz B, Beltrian M, et al. The Mexican experience in the use of vaginal sildenafil in patients with poor endometrial response. International Congress Series. 2004; 1271; 19-21.

32. Zinger M, Liu JH, Thomas MA. Successful use of vaginal sildenafil citrate in two infertility patients with Asherman’s syndrome. J Womens Health (Larchmt). 2006; 15(4): 442-444.

33. AbdelKader Fahmy A, ElSokkary M, Sayed S. The value of oral sildenafil in the treatment of female infertility: a randomized clinical trial. Life Sci J. 2015; 12(4): 78-82.

34. Mangal S, Mehrishi S. To study and compare the effect of vaginal sildenafil and estradiol valerate on endometrial thickness, blood flow and pregnancy rates in infertile women undergoing intrauterine insemination. Int J Reprod Contracept Obstet Gynecol. 2016; 5(7): 2274-2277.

35. Margreiter M, Weghofer A, Feichtinger W. Vaginal sildenafil in patients with poor endometrial development undergoing in vitro fertilization. Fertil Steril. 2004; 82(2): 140.

36. Dzieciol M, Staniczuk E, Noszczyk-Nozak A, Michlik K, Kozdrowski R, Nizanski W, et al. The influence of Sildenafil citrate on uterine tissue perfusion and the cardiovascular system during the luteal phase of the ovarian cycle in cows. Acta Histochem. 2014; 116(2): 377-381.

37. Vidal C, Crespo J, Bellver J, Bosch E, Remohi J, Pellicer A. Sildenafil improves assisted reproduction outcome in bad prognosis patients. Fertil Steril. 2004; 82(2): S241.